Evidence map›Paper›PMID 39546933›Full record

ArticleBioorganic & medicinal chemistry2024

Synthesis and structure-activity relationship of boronic acid bioisosteres of combretastatin A-4 as anticancer agents.

Yali Kong, Michael C Edler, Ernest Hamel, Asa R Britton-Jenkins, Omar Gillan, Susan L Mooberry, David Mu, Milton L Brown

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioorganic & medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yali KongDepartment of Biomedical and Translational Sciences, Macon & Joan Brock Virginia Health Sciences at Old Dominion University, Norfolk, VA 23507, United States. Electronic address: Kongy@odu.edu.
Michael C EdlerDepartment of Medical and Molecular Genetics, United States; School of Medicine, Indiana University, Indianapolis, IN 46202, United States.
Ernest HamelMolecular Pharmacology Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, United States.
Asa R Britton-JenkinsDepartment of Biomedical and Translational Sciences, Macon & Joan Brock Virginia Health Sciences at Old Dominion University, Norfolk, VA 23507, United States.
Omar GillanDepartment of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, United States.
Susan L MooberryDepartment of Pharmacology, UT Health, San Antonio, TX 78229, United States.
David MuDepartment of Biomedical and Translational Sciences, Macon & Joan Brock Virginia Health Sciences at Old Dominion University, Norfolk, VA 23507, United States; Leroy T. Canoles, Jr. Cancer Research Center, Macon & Joan Brock Virginia Health Sciences at Old Dominion University, Norfolk, VA 23507, United States.
Milton L BrownDepartment of Internal Medicine, Macon & Joan Brock Virginia Health Sciences at Old Dominion University, Norfolk, VA 23507, United States. Electronic address: Brownml@odu.edu.

Funding

CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

The boronic acid group plays an important role in drug discovery. Following our discovery of a boronic acid analog of combretastatin A-4 (CA-4), a series of analogs featuring a boronic acid group on the C phenyl ring of CA-4 was synthesized and evaluated for cytotoxicity, as well as for their ability to inhibit tubulin polymerization, inhibit the binding of [

Indexed as

Antineoplastic AgentsBoronic AcidsColchicineStilbenesTubulinCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorHumansMicrotubulesMolecular StructureStructure-Activity RelationshipTubulin ModulatorsAntineoplastic AgentsBoronic AcidsColchicinefosbretabulinStilbenesTubulinTubulin Modulators

Identifiers

PMID39546933
PMCPMC11645202

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.